par Salgado, Roberto;Denkert, Carsten;Campbell, Christine;Savas, Peter;Nucifero, Paolo;Aura, Claudia Monica;de Azambuja, Evandro ;Eidtmann, Holger;Ellis, Catherine;Baselga, José;Piccart-Gebhart, Martine ;Michiels, Stefan ;Bradbury, Ian;Sotiriou, Christos ;Loi, Sherene
Référence JAMA oncology, 1, 4, page (448-454)
Publication Publié, 2015-07
Référence JAMA oncology, 1, 4, page (448-454)
Publication Publié, 2015-07
Article révisé par les pairs
Résumé : | The presence of tumor-infiltrating lymphocytes (TILs) is associated with improved outcomes in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer treated with adjuvant trastuzumab and chemotherapy. The prognostic associations in the neoadjuvant setting of other anti-HER2 agents and combinations are unknown. |